SHSixten Harborg

Sixten Harborg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sixten Harborg has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Re: “Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer”

    by Sixten Harborg, Signe Borgquist, Deirdre Cronin-Fenton

    Was not provided for this article.

  • Open Access

    Postdiagnosis Statin Use and Breast Cancer Mortality

    by Sixten Harborg, Lars Pedersen, Henrik T. Sørensen, Thomas P. Ahern, Deirdre Cronin-Fenton, Signe Borgquist

    Importance: Emerging evidence suggests that cholesterol plays a role in breast cancer (BC) metabolism, raising the possibility that cholesterol-lowering medications, such as statins, may improve BC prognosis. Objective: To evaluate the association between postdiagnosis statin initiation and BC mortality using an emulated target trial approach. Design, Setting, and Participants: This observational cohort study using a target trial framework included 96 924 women diagnosed with stage I to III BC from 2000 to 2021 from Nationwide Danish registries, including the Danish Breast Cancer Group’s clinical database and the Danish National Prescription Registry. Women with prior invasive BC or prediagnosis use of cholesterol-lowering medication were excluded. Eligible patients were duplicated into a cloned cohort and assigned to 1 of 2 treatment strategies: statin initiation within 36 months postdiagnosis or no statin initiation. Patients were followed up until deviation from the assigned strategy, emigration, death, 10 years of follow-up, or October 5, 2022. Exposures: Initiation of any statin within 36 months after BC diagnosis. Main Outcomes and Measures: The primary outcome was BC mortality. Secondary outcomes included all-cause mortality. Hazard ratios (HRs) and 95% CIs were estimated using inverse probability of censoring weighted (IPCW) Cox regression models with a robust variance estimator. Results: A total of 66 952 patients with BC were enrolled in the emulated target trial (17 152 [27.6%] were aged 50-59 years); 4851 (7.2%) initiated statins within 36 months after diagnosis. Over 606 266 person-years of follow-up, 9130 patients died from BC and 19 679 from any cause. The 10-year risk of breast cancer mortality was 11.8% among statin initiators and 13.5% among noninitiators, corresponding to a risk difference of 1.7% (95% CI, 0.5% to 3.0%). A similar difference was observed for all-cause mortality (23.3% vs 24.5%; risk difference, 1.2%; 95% CI, –0.1% to 2.5%). IPCW analysis yielded an HR of 0.90 (95% CI, 0.85 to 0.95) for BC mortality and 0.92 (95% CI, 0.85 to 1.00) for all-cause mortality among statin initiators vs noninitiators. Conclusions and Relevance: In this cohort study, among 66 952 women with early BC, postdiagnosis statin initiation was associated with a modest reduction in BC and all-cause mortality. These findings support further investigation into the potential role of statins as an adjunct to standard adjuvant BC treatment.


  • Open Access

    Understanding the role of obesity in endocrine therapy for postmenopausal breast cancer: significance of the BIG 1–98 and ATAC trial data

    by Sixten Harborg, Signe Borgquist

    Obesity is a known risk factor for poor breast cancer outcomes, but its impact on endocrine therapy efficacy remains unclear. While the ATAC trial suggests reduced effectiveness of aromatase inhibitors (AIs) in women with obesity, the BIG 1–98 trial found no significant differences. Clinical and biological evidence indicates that obesity may impair AI efficacy by increasing aromatase activity and altering drug metabolism, whereas tamoxifen remains largely unaffected. Pooling data from these trials would enable detailed analyses across body composition categories, addressing discrepancies and potentially guide personalized treatment strategies. Understanding the interaction between obesity and endocrine therapy is crucial for optimizing breast cancer care.


  • Open Access

    Metabolic syndrome is associated with breast cancer mortality: A systematic review and meta‐analysis

    by Sixten Harborg, Helene Borup Larsen, Stine Elsgaard, Signe Borgquist

    Background: This systematic review and meta‐analysis assesses the association between metabolic syndrome and breast cancer (BC) outcomes in BC survivors.Methods: Systematic searches were carried out in PubMed and Embase using variations of the search terms: breast neoplasms (population), metabolic syndrome (exposure), and survival (outcome). Metabolic syndrome was characterized according to the American Heart Association, which includes the presence of three out of five abnormal findings among the risk factors: high blood pressure, high triglycerides, low high‐density lipoprotein, high fasting glucose, and central obesity. Data were obtained from observational studies and randomized controlled trials that utilized survival statistics and reported survival ratios to investigate how the presence of metabolic syndrome at the time of BC diagnosis is associated with BC outcomes. Study data were independently extracted by two authors, and effect sizes were pooled using random‐effects models.Results: From the 1019 studies identified in the literature search, 17 were deemed eligible. These encompassed 42,135 BC survivors. The pooled estimates revealed that BC survivors who had metabolic syndrome at the time of their BC diagnosis experienced increased risk of recurrence (HR 1.69, 95% CI: 1.39–2.06), BC mortality (HR 1.83, 95% CI: 1.35–2.49), and shorter disease‐free survival (HR 1.57, 95% CI: 1.36–1.81) compared to BC survivors without metabolic syndrome.Conclusions: Among BC survivors, metabolic syndrome was associated with inferior BC outcomes. This necessitates the creation of clinical guidelines that include metabolic screening for BC survivors. Further research should identify effective interventions to reduce the prevalence of metabolic syndrome among BC survivors to improve metabolic health and BC outcomes.


  • Open Access

    Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors

    by Sixten Harborg, Deirdre Cronin-Fenton, Maj-Britt Raaby Jensen, Thomas P. Ahern, Marianne Ewertz, Signe Borgquist

    Body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) is the standard metric for classifying adiposity. High BMI has repeatedly been shown to be associated with a poorer prognosis of early breast cancer.1-3 Yet, the mechanisms by which obesity affects prognosis remain unclear. One mechanism may be reduced clinical efficacy of adjuvant treatment (eg, endocrine treatment with aromatase inhibitors [AI] for hormone receptor–positive [HR+] postmenopausal breast cancer) in patients with obesity.4 HR+ breast cancer is the most common subtype of breast cancer among postmenopausal women, accounting for 80% of all cases.5 The adjuvant endocrine therapy of choice for this patient group is an AI.6 Aromatase is highly expressed in adipose tissue, where it catalyzes the biotransformation of androgens into estrogen; it is also the target enzyme for AIs in the context of treating HR+ breast cancer in postmenopausal women.7,8


  • Top Cited Papers

    New Horizons: Epidemiology of Obesity, Diabetes Mellitus, and Cancer Prognosis

    by Sixten Harborg, Kasper A Kjærgaard, Reimar Wernich Thomsen, Signe Borgquist, Deirdre Cronin-Fenton, Cathrine F Hjorth

    The global prevalence of obesity and diabetes mellitus has increased in parallel with increasing cancer incidence, due to environmental and lifestyle factors and population aging. Metabolic diseases are associated with increased cancer risk, so a growing number of patients with cancer have coexistent obesity and/or diabetes mellitus. In this narrative review, we highlight recent evidence on the clinical impact of obesity and diabetes mellitus on the prognosis of prostate, breast, and colorectal cancer, and provide an overview of the underlying mechanisms. There is evidence that obesity is associated with increased risk of recurrence, and all-cause and cancer-specific mortality among adults with prostate, breast, and colorectal cancer. Diabetes mellitus is associated with increased all-cause and cancer-specific mortality for these 3 cancers, beyond any impact of obesity. Evidence also suggests increased risk of colorectal cancer recurrence in patients with diabetes mellitus. The underlying mechanisms are multifactorial and likely include hormonal imbalances and chronic inflammation that promote cancer cell growth. Obesity and diabetes mellitus are associated with increased risk of complications and side effects of cancer treatment. Associated comorbidities such as impaired kidney function, cardiovascular disease, and neuropathies may preclude the use of guideline cancer treatment and are competing causes of death. Cancer patients with metabolic diseases require a designated clinical program and a multidisciplinary approach involving oncologists, endocrinologists, surgeons, nutritionists, and physiotherapists, to ensure coordinated and optimized patient care.


  • Open Access

    Obesity and breast cancer prognosis: pre-diagnostic anthropometric measures in relation to patient, tumor, and treatment characteristics

    by Sixten Harborg, Maria Feldt, Deirdre Cronin-Fenton, Marie Klintman, Susanne O. Dalton, Ann H. Rosendahl, Signe Borgquist

    Purpose: Examine the association between obesity and clinical outcomes in early breast cancer and assess if patient, tumor, and treatment characteristics modify such associations in Malmö Diet and Cancer Study patients (MDCS). Methods: The MDCS enrolled 17,035 Swedish women from 1991 to 1996. At enrollment, participants' body mass index (BMI), waist circumference and body fat percentage measures were collected. We identified all female MDCS participants with invasive breast cancer from 1991 to 2014. Follow-up began at breast cancer diagnosis and ended at breast cancer recurrence (BCR), death, emigration, or June 8, 2020. The World Health Organization guidelines were used to classify BMI, waist circumference, and body fat percentage into three categories of healthy weight, overweight, and obesity. We fit Cox regression models to compute adjusted hazard ratios (HRs) with 95% confidence intervals (CI) of BCR according to body composition. To evaluate effect measure modification, we stratified Cox models by patient, tumor, and treatment characteristics. Results: In total, 263 BCRs were diagnosed over 12,816 person-years among 1099 breast cancer patients with a median follow-up of 11.1 years. Obesity according to BMI (HR = 1.44 [95%CI 1.00–2.07]), waist circumference (HR = 1.31 [95%CI 0.98–1.77]), and body fat percentage (HR = 1.41 [95%CI 1.02–1.98]) was associated with increased risk of BCR compared with healthy weight. Obesity was stronger associated with BCR in patients with low socioeconomic position (HR = 2.55 [95%CI 1.08–6.02]), larger tumors > 20 mm (HR = 2.68 [95%CI 1.42–5.06]), estrogen-receptor-negative breast cancer (HR = 3.13 [95%CI 1.09–8.97]), and with adjuvant chemotherapy treatment (HR = 2.06 [95%CI 1.08–4.31]). Conclusion: Higher pre-diagnostic BMI, waist circumference, and body fat percentage was associated with increased risk of BCR. The association between obesity and BCR appears dependent on patient, tumor, and treatment characteristics.


  • Open Access

    Abstract P4-07-06: Circulating lipids and breast cancer survival in the Malmö diet and cancer study

    by Sixten Harborg, Thomas P Ahern, Maria Feldt, Ann H Rosendahl, Deirdre Cronin-Fenton, Olle Melander, Signe Borgquist

    Rationale: Overweight and obesity are associated with inferior prognosis in breast cancer. The explanation is considered multifactorial, and dyslipidemia may be a contributing factor. The purpose of this study was to examine the association between circulating lipids and breast cancer outcomes in patients enrolled in the Malmö Diet and Cancer Study (MDCS). Patients and methods: Circulating lipid levels were measured in the blood sampled upon enrollment in the female MDCS cohort (N=17,035). We identified all MDCS participants with incident invasive breast cancer diagnosed between 1991-2014. The follow-up time began at breast cancer diagnosis and continued until the first event of breast cancer recurrence, death, emigration, or five years of follow-up. We estimated the incidence rates of recurrence at five years and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI) of breast cancer recurrence as well as all-cause mortality according to cohort-specific tertiles of apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B). Results: We enrolled 850 eligible patients. During the five years of follow up, 90 invasive recurrences with over 3,807 person-years occurred. In multivariable analyses, high levels of Apo B were associated with an increased rate of recurrence (tertile 3 vs. 1, HR= 2.30 [95% CI: 1.13-4.68]). However, high levels of Apo B were not associated with all-cause mortality (tertile 3 vs. 1, HR= 1.23 [95%CI: 0.68-2.25]). We observed no associations between levels of Apo A-1 and recurrence (tertile 3 vs. 1, HR= 1.34 [95%CI: 0.70-2.58]) or all-cause mortality (tertile 3 vs. 1, HR=1.12 [95%CI: 0.61-2.05]). Conclusion: High pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. Circulating Apo A-1 was not associated with breast cancer outcome. These results warrant further investigation into the importance of lipid-regulation in breast cancer patients. Citation Format: Sixten Harborg, Thomas P Ahern, Maria Feldt, Ann H Rosendahl, Deirdre Cronin-Fenton, Olle Melander, Signe Borgquist. Circulating lipids and breast cancer survival in the Malmö diet and cancer study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-07-06.

  • Open Access

    Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study

    by Maria Inasu, Maria Feldt, Helena Jernström, Signe Borgquist, Sixten Harborg


  • Open Access

    Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study

    by Sixten Harborg, Thomas P. Ahern, Maria Feldt, Ann H. Rosendahl, Deirdre Cronin-Fenton, Olle Melander, Signe Borgquist

    Purpose: Examine the association between circulating lipids and breast cancer outcomes in patients enrolled in the Malmö Diet and Cancer Study (MDCS). Patients and methods: Circulating lipid levels were measured in blood sampled upon enrollment in the female MDCS cohort (N = 17,035). We identified all MDCS participants with incident invasive breast cancer diagnosed between 1991 and 2014. Follow-up time began at breast cancer diagnosis and continued until the first event of breast cancer recurrence, death, emigration, or 5 years of follow-up. We estimated the incidence rates of recurrence at 5 years and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI) of breast cancer recurrence as well as all-cause mortality according to cohort-specific tertiles of apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B). Results: We enrolled 850 eligible patients. During the 5 years of follow-up, 90 invasive breast cancer recurrences were diagnosed over 3807 person-years. In multivariable analyses, high baseline levels of Apo B were associated with an increased rate of recurrence (tertile 3 vs. 1, HR = 2.30 [95% CI 1.13–4.68]). However, high baseline levels of Apo B were not associated with all-cause mortality (tertile 3 vs. 1, HR = 1.23 [95% CI 0.68–2.25]). We observed no associations between levels of Apo A-1 and recurrence (tertile 3 vs. 1, HR = 1.34 [95% CI 0.70–2.58]) or all-cause mortality (tertile 3 vs. 1, HR = 1.12 [95% CI 0.61–2.05]). Conclusion: High pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. Circulating Apo A-1 was not associated with breast cancer outcomes.